Necrotizing Fasciitis Secondary To Bevacizumab Treatment For Metastatic Rectal Adenocarcinoma
![](/xmlui/themes/Mirage2//images/mime2.png)
View/ Open
Date
2014Author
Şendur, Mehmet A. N.
Aksoy, Sercan
Özdemir, Nuriye Yıldırım
Zengin, Nurullah
xmlui.mirage2.itemSummaryView.MetaData
Show full item recordAbstract
Bevacizumab is a recombinant humanized monoclonal antibody that selectively blocks the activity of vascular endothelial growth factor (VEGF) receptor and it is used in metastatic colorectal patients. We present here a case of fatal necrotizing fasciitis in a patient during bevacizumab treatment for colorectal cancer. In our review of the literature, necrotizing fasciitis was not reported before or during bevacizumab treatment.
URI
https://doi.org/10.4103/0253-7613.125195https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3912798/
http://hdl.handle.net/11655/15207